Cytek Biosciences Inc (CTKB)vsMedtronic PLC (MDT)
CTKB
Cytek Biosciences Inc
$4.09
-5.54%
HEALTHCARE · Cap: $559.19M
MDT
Medtronic PLC
$81.67
-0.16%
HEALTHCARE · Cap: $94.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Medtronic PLC generates 17280% more annual revenue ($35.48B vs $204.17M). MDT leads profitability with a 13.0% profit margin vs -36.2%. MDT earns a higher WallStSmart Score of 61/100 (C+).
CTKB
Hold41
out of 100
Grade: D
MDT
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.8%
Fair Value
$7.62
Current Price
$4.09
$3.53 discount
Margin of Safety
+10.3%
Fair Value
$89.60
Current Price
$81.67
$7.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 20.0%
Generating 2.1B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -22.6% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Weak financial health signals
Earnings declined 11.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : MDT
The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : MDT
The primary concerns for MDT are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.19 — expect wider price swings.
MDT is growing revenue faster at 8.7% — sustainability is the question.
MDT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
MDT scores higher overall (61/100 vs 41/100). CTKB offers better value entry with a 42.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is at the forefront of multi-parameter flow cytometry, offering advanced cell analysis solutions that drive innovation in the life sciences industry. The company's proprietary technologies play a critical role in pivotal research fields such as immunology, cancer diagnostics, and drug development, addressing the growing demand for high-precision cellular analysis. Cytek’s dedication to innovation, coupled with its robust customer support, positions it as a significant player within the biotechnology sector. With a comprehensive product range and a solid market footprint, Cytek is well-equipped to facilitate groundbreaking discoveries that can dramatically enhance healthcare outcomes.
Medtronic PLC
HEALTHCARE · MEDICAL DEVICES · USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?